Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce
This study aims to describe an association between the Pfizer-BioNTech (BNT162b2) vaccine and decreased risk of symptomatic and asymptomatic infections with SARS-CoV-2 in hospital employees.// 6.5.2021
Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses
The factors responsible for the spectrum of coronavirus 19 (COVID-19) disease severity and the genesis and nature of protective immunity against COVID-19 remain elusive. Multiple studies have investigated the immune responses to COVID-19 in various populations, including those without evidence of CO …// 4.5.2021
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Two doses of BNT162b2 are highly effective across all age groups (≥16 years, including older adults aged ≥85 years) in preventing symptomatic and asymptomatic SARS-CoV-2 infections and COVID-19-related hospitalisations, severe disease, and death, including those caused by the B.1.1.7 SARS-CoV-2 variant. There were marked and sustained declines in SARS-CoV-2 incidence corresponding to increasing vaccine coverage. These findings suggest that COVID-19 vaccination can help to control the pandemic.// 5.5.2021
Onko mystisten koronarokotteen jälkeen saatujen veritulppien syy rokotustekniikka?– Euroopan lääkevirasto tutkii
Veritulppatapausten yhteyttä rokotustekniikkaan tutkitaan. Tanskassa ja Ruotsissa aspirointia suositellaan nyt varotoimenpiteenä, Norjassa ja Suomessa ei.// 7.4.2021
Nature Medicine - Breakthrough infections of SARS-CoV-2 occurring 12 or more days after the first dose of the BNT162b2 mRNA vaccine were associated with lower viral loads than those found in... // 29.3.2021
SARS-CoV-2 infection risk among unvaccinated is negatively associated with community-level vaccination rates
Mass vaccination has the potential to curb the current COVID-19 pandemic by protecting vaccinees from the disease and possibly lowering the chance of transmission to unvaccinated individuals. The high effectiveness of the widely-administered BNT162b vaccine in preventing not only the disease but also infection suggests a potential for a population-level effect, critical for disease eradication. // 29.3.2021
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA
mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection was 90% for full immunization (≥14 days after second dose) and 80% for partial immunization (≥14 days after first dose but before.... // 29.3.2021
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals - Full Text View
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals - Full Text View.
Nature Reviews Immunology - In this Perspective, Cobey, Larremore, Grad and Lipsitch argue that dose-sparing regimens of COVID-19 vaccines can reduce disease incidence, prevalence and burden and... // 1.4.2021
Why does drug resistance readily evolve but vaccine resistance does not?
Why is drug resistance common and vaccine resistance rare? Drugs and vaccines both impose substantial pressure on pathogen populations to evolve resistance and indeed, drug resistance typically emerges soon after the introduction of a drug. // 29.3.2021
Pfizer-BioNTech And Moderna Covid-19 Vaccines: Here Are 5 Differences
Now there are two. The Moderna Covid-19 coronavirus vaccine received emergency use authorization from the U.S. FDA to join the Pfizer/BioNTech vaccine. //19.12.2020
%2Fimg-s3.ilcdn.fi%2Fcf29541b137849c19b12dd2f3338a8160d3ca605772b98b7abeb8a20d114446e.jpg?width=92&height=&ar=&mode=&format=avif&dpr=2)
